A range of therapeutic classes will be evaluated in Strata PATH including:
- targeted therapies
- antibody-drug conjugates
- immunotherapies
- angiogenesis inhibitors
Learn more about currently open Strata PATH arms on clinicaltrials.gov.
Who is eligible?
Strata PATH is currently enrolling patients with advanced cancer. Patients must be positive for specific biomarker profiles and have not previously been treated with the identified class of therapy. Other eligibility criteria must also be met.
Eligibility for several arms of Strata PATH is based on proprietary quantitative RNA algorithms Strata Oncology developed using its clinical molecular database that ties together real-world outcomes with genomic and transcriptomic data from tens of thousands of patients.
Learn more about Strata’s testing platform that uses a single tissue sample to provide treatment selection across therapeutic modalities.